Based on the network pharmacological analysis, 9 hug targets (CCL2, IL10, PTGS2, TNF, MAPK1, IL6, CXCL8, TP53, and VEGFA) were collected and validated as the therapeutic targets of FHD on NS in vivo. This evidence concerns the gene MAPK1 and hypoalphalipoproteinemia, primary, 1.